Thursday, June 4, 2020

Nottingham-based Oncimmune Holdings appoint new CEO

Nottingham-based Oncimmune Holdings, the cancer detection firm, has appointed Adam Hill as Chief Executive Officer.

His appointment follows founder Geoffrey Hamilton-Fairley’s decision to step down as Chief
Executive Officer and into a new role as Vice Chairman of the Company’s Board of Directors
and is effective 1st October 2018.

Dr Hill joined Oncimmune as Chief Medical Officer and Chief Scientific Officer and Executive
Director earlier this year from McLaren Applied Technologies, where he was Chief Strategy
Officer and responsible for its portfolio of health programmes, co-developed in partnership
with blue chip pharma and medical device companies.

Adam is a clinician-scientist, with a career built in industry, academia and care delivery. During his career, Adam has been responsible for developing technology and commercial strategies in the medical device and diagnostics industry, and has held senior leadership roles at private and listed companies, supplemented by advisory and government policy appointments.

Since joining Oncimmune, Dr Hill has been leading both the R&D team and a strategic review of the Company, with a view to identifying and capitalising on the opportunities presented by Oncimmune’s proprietary auto-antibody-based platform for individual profiling of cancer related antigens.

Mr Hamilton-Fairley, an early pioneer in the field of cancer immunodiagnostics, joined Oncimmune in 2005 as it was established as a spin out of Nottingham University, and led the Company’s transition to a commercial phase company with the launch in the US of two early detection blood based tests in lung and liver cancer.

He also led the geographic expansion with important collaborative partnerships in China, Europe and the Middle East. Mr Hamilton-Fairley will transition to a new created role of Vice Chairman of the Board of Directors and assist in developing the new senior leadership team as well as continuing to support the Company on certain key strategic projects.

Meinhard Schmidt, Non-Executive Chairman of Oncimmune, commented: “We would like to thank Geoffrey for his vision and commitment over the last 13 years, which has led to Oncimmune becoming a leader in immunodiagnostics for cancer.

“He has built an experienced international team, strong internal science and a development platform with the capability to attract research partnerships and to establish next generation technology with new collaborations worldwide as the portfolio of programmes and products expands beyond the lung and liver tests to maximise shareholder value.

“We are delighted to welcome Adam as Oncimmune’s new CEO. His experience in the science, medicine and technology of personalised approaches to diagnostics and optimisation of healthcare delivery are an excellent fit for the Company’s ambitions as we progress towards realising our goals of delivering early detection and improved care for cancer patients.”

Geoffrey Hamilton-Fairley commented: “It has been a great experience leading Oncimmune from its spin out from Nottingham University and a team of dedicated colleagues and research collaborators who have been working together to transform the treatment of cancer through immunodiagnostics leading to early detection and improved care and outcomes.

“The Company is well positioned for an exciting future and it is now time to transition to new leadership who will take our products and technology through clinical development and broad global commercialisation, and Adam has demonstrated that he is the ideal leader to deliver the next phase of Oncimmune’s growth. My thanks and appreciation to the extended Oncimmune team and partners, past and present.”

Adam Hill commented: “Oncimmune has a strong and proprietary position in immune
profiling of cancer, and a compelling pipeline of clinical and commercial phase assets that will help unlock the potential of personalised immunodiagnostics for a broad portfolio of cancer indications.

“As the field of oncology sits on the cusp of dramatically improved cancer survivorship, I look forward to working with the Company’s experienced Board, and its highly talented executive and scientific teams to take Oncimmune’s immunodiagnostic solutions through clinical development and into the hands of clinicians to improve patient outcomes.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £33.60 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.






Latest news

Trio of non-executive directors join Lincolnshire Chamber of Commerce Board

Three new non-executive directors have been appointed to the Board of Lincolnshire Chamber of Commerce. Nicola Langton, Head of Business Support at EBP, Roy Colclough, previous...

Sygnature Discovery expands capabilities with new acquisition

Sygnature Discovery has acquired Alderley Oncology, a focused in vivo pharmacology service provider which undertakes in vivo services for cancer drug discovery, strengthening its...

Sleaford Renewable Energy Plant acquired

Greencoat Capital LLP has acquired Sleaford Renewable Energy Plant in Lincolnshire from Glennmont Partners. The investment was made with funds from RPMI Railpen, the investment...

225 jobs on the line at Forterra

Approximately 225 jobs could be lost at Forterra plc, the Northamptonshire-headquartered producer of manufactured masonry products, under new proposals to mitigate the impact of...

Work to transform Derby into one of the world’s best digitally connected cities begins

Derby is celebrating a major milestone in its digital transformation as work begins to extend its full fibre network to reach almost every home...

Related news

Rolls-Royce to cut 1,500 jobs in the East Midlands

Rolls-Royce is to cut 1,500 jobs in the East Midlands. The news comes after the company confirmed in May that at least 9,000 jobs would...

Trio of non-executive directors join Lincolnshire Chamber of Commerce Board

Three new non-executive directors have been appointed to the Board of Lincolnshire Chamber of Commerce. Nicola Langton, Head of Business Support at EBP, Roy Colclough, previous...

Sygnature Discovery expands capabilities with new acquisition

Sygnature Discovery has acquired Alderley Oncology, a focused in vivo pharmacology service provider which undertakes in vivo services for cancer drug discovery, strengthening its...

Sleaford Renewable Energy Plant acquired

Greencoat Capital LLP has acquired Sleaford Renewable Energy Plant in Lincolnshire from Glennmont Partners. The investment was made with funds from RPMI Railpen, the investment...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close